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Abstract
Background: Retinoid X receptors (RXRs) are members of the nuclear receptor (NR) superfamily that mediate
signalling by 9-cis retinoic acid, a vitamin A derivative. RXRs play key roles not only as homodimers but also
as heterodimeric partners, e.g., for retinoic acid receptors, vitamin D receptors, and peroxisome proliferator-
activated receptors. The NR family may also play important roles in the development of emphysema. However, the
role of RXRs in the pathogenesis of emphysema is not well defined.
Methods: We developed a novel RXR partial agonist (NEt-4IB) and investigated its effect and mechanism compared to
a full agonist (bexarotene) in a murine model of emphysema. For emphysema induction, BALB/c mice received
intraperitoneal cigarette smoke extract (CSE) or intratracheal porcine pancreas elastase (PPE). Treatment with
RXR agonists was initiated before or after emphysema induction.
Results: Treatment with NEt-4IB significantly suppressed the increase in static lung compliance and emphysematous
changes in CSE-induced emphysema and PPE-induced established and progressive emphysema. NEt-4IB significantly
suppressed PPE-induced neutrophilic airway inflammation and the levels of keratinocyte chemoattractant (KC), C-X-C
motif ligand5 (CXCL5), interferon (IFN)-γ and IL-17. NEt-4IB also improved the matrix metalloproteinase-9 (MMP-9)/
tissue inhibitor of metalloproteinase-1 (TIMP-1) imbalance and the reduced anti-oxidant activity in bronchoalveolar
lavage (BAL) fluid. NEt-4IB suppressed PPE-induced vascular endothelial growth factor (VEGF) expression in the airway.
Treatment with NEt-4IB and bexarotene significantly suppressed the increase in static lung compliance and
emphysematous changes. However, adverse effects of RXR agonists, including hypertriglyceridemia and hepatomegaly,
were observed in bexarotene-treated mice but not in NEt-4IB-treated mice.
Conclusion: These data suggest that RXRs play crucial roles in emphysema and airway inflammation, and novel partial
RXR agonists could be potential therapeutic strategies for the treatment of PPE- and CSE-induced emphysema.
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Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by airflow obstruction that is not fully revers-
ible, leading to respiratory insufficiency and functional
disability [1]. Existing therapeutic options for COPD can
reduce symptoms and the frequency and severity of exacer-
bations. Nonetheless, these therapies are not able to effect-
ively preserve lung function or completely palliate
symptoms in COPD [1]. Therefore, new anti-inflammatory
therapeutic strategies are required.
Recent investigations have demonstrated that nuclear
receptors (NRs) are related to the development of
COPD. Mice lacking peroxisome proliferator-activated
receptor γ (PPARγ) were reported to exhibit enhanced
cigarette smoke (CS)-induced airway inflammation and
emphysematous changes in the lungs [2]. Rosiglitazone,
which is an agonist of PPARγ, attenuated CS-induced
airway inflammation and emphysematous changes in the
lungs [3]. Gene expression of liver X receptor (LXR) in
the lungs was increased in COPD patients, and an LXR
agonist exerted anti-inflammatory effects on C-X-C
motif ligand 10 (CXCL10), C-C motif ligand 5 (CCL5),
and IL-10 production by alveolar macrophages [4]. Ret-
inoid X receptors (RXRs) are NRs that control gene
transcription in a manner dependent on ligand binding
[5] and act as homodimers or heterodimers with PPARs,
LXRs, and other NRs [6–8]. These data suggest that
RXRs may be potential targets for the prevention and
management of COPD. The efficacy of RXR agonists for
treatment of several diseases has been reported. For ex-
ample, the RXR full agonist bexarotene has been used
for the treatment of cutaneous T cell lymphoma [9] and
has been reported to have therapeutic potential for
treatment of animal models of type-2 diabetes [10],
Alzheimer’s disease [11], and Parkinson’s disease [12].
We previously reported that a new RXR full agonist,
NEt-TMN, has the potential to reduce adverse effects
while retaining desired activities [13]. However, RXR
full agonists including NEt-TMN and bexarotene also
induce various adverse events, such as weight gain,
hepatomegaly, and blood triglyceride elevation, when
used to treat underlying diseases [13].
Partial agonists have only partial efficacy on receptors
relative to full agonists and exert both agonistic and an-
tagonistic effects. Clinically, partial agonists can be used
to activate receptors to give a desired submaximal re-
sponse and prevent overstimulation or prolonged activa-
tion of receptors, which could cause adverse events. It
was reported that activation of LXRα/RXRα induced in-
creased levels of triglycerides in the serum [14]. To avoid
severe adverse events, we planned to induce moderate
activation of RXRs sufficient to regulate airway inflam-
mation and focused on the production of novel RXR
partial agonists with lower maximum capacities to
activate RXRs than that of full RXR agonists. We finally
developed the innovative RXR partial agonist NEt-4IB,
55% of the activity of a full agonist in a luciferase re-
porter assay [15]. In addition, we previously reported
that long-term administration of NEt-4IB induced no
significant adverse events [15].
In the present study, to determine whether RXRs play
important roles in the development of emphysema and
whether novel RXR partial agonists may be promising
options for the treatment of emphysema, we investigated
the therapeutic potential and adverse effects of these
molecules on emphysema development and airway in-
flammation in a murine model of emphysema.
Methods
Animals
Female BALB/c mice at 8 weeks of age were purchased
from Charles River Japan, Inc. (Yokohama, Japan). All
experimental animals used in the present study were
housed under a protocol approved by the Institutional
Animal Care and Use Committee of Okayama University
Medical School (Okayama, Japan).
COPD induction by cigarette smoke extract
For the preparation of cigarette smoke extract (CSE),
3R4F reference cigarettes were purchased from the
University of Kentucky. One non-filtered cigarette
was burned, and the smoke was passed through 8 ml
PBS by connecting to a vacuum pump with a con-
stant air flow of 2 L/min. The extract was used when
the pH was between 6.2 and 6.4, and the OD at 320
nm was between 1.600 and 1.900. The extract was
prepared fresh for each experiment and used for ad-
ministration after adjusting the pH to between 7.00
and 7.40 and filtering through a 0.2-μm-pore filter to
remove particles and bacteria. Mice were anaesthe-
tized with isoflurane for administration of CSE. The
experimental mice received 400 μl CSE intraperitone-
ally on days 0, 7, 14, and 21. The control mice re-
ceived 400 μl phosphate buffered saline (PBS) at the
same time points.
COPD induction by porcine pancreas elastase
Mice were anaesthetized with isoflurane for the adminis-
tration of porcine pancreas elastase (PPE) (Sigma-Aldrich,
St. Louis, MO, USA). The experimental mice received 50
U/kg PPE dissolved in 40 μl PBS via the trachea. The con-
trol mice received 40 μl PBS at the same time points.
Administration of the novel RXR partial agonist and
bexarotene
The mice orally received a novel RXR partial agonist
(0.005, 0.015%, or 0.05% NEt-4IB; see Additional file 1)
or a full RXR agonist (0.015% bexarotene). In detail,
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mice were fed standard diet containing RXR agonist
(mixed feed) with free eating system by mice. The con-
trol mice received vehicle. The changes of the weight of
feed in each cage were measured every day or ever week
according to the study protocol.
Determination of static lung compliance
A flexiVent small-animal ventilator (SCIREQ, Montreal,
PQ, Canada) was used to assess static lung compliance
(Cst), which is a measurement of the elasticity of the
lungs. It was calculated from the pressure volume curves
using flexiVent software (version 5.0) [16], as previously
described. In brief, the mice were anaesthetized with
150 mg/kg ketamine and 10 mg/kg xylazine (Kyoritsu
Seiyaku, Tokyo, Japan) by intraperitoneal injection. The
mice were tracheostomized with a 5-mm section of me-
tallic tubing (18 G cannula) and ventilated at 150
breaths/min with a tidal volume of 10 ml/kg and a posi-
tive end-expiratory pressure of 3 cmH2O, and Cst was
then measured.
Bronchoalveolar lavage fluid
Lungs were lavaged with Hanks’ balanced salt solution via
the tracheal tube (2 × 1ml, 37 °C), and the number of cells in
the bronchoalveolar lavage (BAL) fluid was counted. Cytos-
pin slides were stained and differentiated in a blinded fashion
by counting at least 200 cells under light microscopy.
Lung histology and morphometric measurements of air
space size
The left lung was inflated by intratracheal instillation
with 10% formalin at a static pressure of 20 cmH2O and
fixed in 10% formalin. The tissue was then embedded in
paraffin, and 2-μm thick sections were stained with
haematoxylin and eosin (H&E). Air space enlargement
was quantified by assessing the mean linear intercept
(Lm) and the destructive index (DI). Ten of tissue image
fields were randomly selected from all parts of the whole
lung at the height of the hilum from each mouse. The
Lm, which represents the average size of the alveoli, was
calculated by counting lines of a defined length, as previ-
ously described [17]. In detail, we put 10 traversed lines
provided at regular intervals on the lung section. A total
number of intercepts with the lung structures on each
traversed line are counted. A total 1000 lines per each
mouse lung were evaluated. Lm is calculated as the ratio
between the sum of the length of traverse lines and the
sum of all the intercepts. The DI, which represents the
proportion of destroyed alveoli among the total alveoli,
was determined by dividing the number of identified
destroyed alveoli. We put 50 counting points on each
image. Only point putting on alveolar and duct space
were counted. If a counting point was surrounded by
normal alveolar or alveolar duct, they are considered as
normal [18, 19]. Destruction was counted when there
were more than two alveolar wall defects, when there
were more than two intraluminal parenchymal rags in
alveolar duct, when clearly abnormal morphology, or
when classic emphysematous changes. More than 3000
alveoli randomly were counted in each group. DI was
represented as percentage of the destructive alveoli as a
fraction of total number of alveoli.
Cytokine and chemokine measurements
The cytokine levels in the BAL fluid and in the supernatants
of homogenized lungs were measured by ELISA, as previ-
ously described [20]. For preparation of lung homogenates,
lung tissue was frozen at − 70 °C immediately after euthan-
asia. The lung tissue was mixed with a PBS-0.1% Triton-
X100 solution containing proteinase inhibitors at a 1:2.5 ratio
of weight per volume (Sigma-Aldrich). The specimens were
homogenized and then centrifuged at 21,480 g for 30min.
The supernatants were frozen at − 80 °C until analysis. All
cytokine and chemokine ELISAs were performed according
to the manufacturer’s instructions. The limits of detection
were 2 pg/ml for keratinocyte chemoattractant (KC), 1.74 pg/
ml for CXCL5, 2 pg/ml for interferon (IFN) -γ, 5 pg/ml for
IL-17A, 1.8 pg/ml for IL-6, 4.8 pg/ml for IL-1β, 7.2 pg/ml for
tumour necrosis factor (TNF)-α, 3 pg/ml for vascular endo-
thelial growth factor (VEGF), 0.014 ng/ml for matrix
metalloproteinase-9 (MMP-9), 3.5 pg/ml for tissue inhibitor
of metaroproteiase-1 (TIMP-1) (R&D Systems, Minneap-
olis, MN, USA), and 40 pg/ml for perforin (Diaclene,
France).
Measurement of anti-oxidant activity in BAL fluid and serum
The anti-oxidant activity in the BAL fluid and the serum
was determined by the bio-anti-oxidant power (BAP)
test using a Free Radical Elective Evaluation FRS4 sys-
tem (Diacron International, Grosseto, Italy), as previ-
ously described [18].
Measurement of serum parameters
Triglyceride (TG), glucose, aspartate transaminase (AST),
alanine aminotransferase (ALT), alkaline phosphatase
(ALP), amylase (AMY), and leucine aminopeptidase
(LAP) levels were measured using a Fuji Dry Chem system
(Dry Chem 4000 V; Fuji Medical Co., Tokyo, Japan).
Statistical analysis
All results were described as the means ± standard error
of the means (SEM). Statistical significance among all
groups was detected by using a one-way ANOVA. Pairs
of groups of samples distributed parametrically were
compared by unpaired two-tailed Student’s t-tests, and
samples distributed nonparametrically were compared
by the Mann-Whitney U test. Significance was assumed
at P values < 0.05.
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Results
The optimal dosage of the novel RXR partial agonist NEt-4IB
in a murine model
We assessed the dose-related effects of the novel RXR
partial agonist NEt-4IB in a murine model of emphy-
sema to determine the optimal dosage of NEt-4IB in an
emphysema model (see Additional files 1, 2). These re-
sults suggested that the optimal concentration of
NEt-4IB in our murine emphysema model was 0.015%;
this concentration has therapeutic efficacy without indu-
cing adverse effects and is consistent with our recent
study in a murine model of asthma [20].
Treatment with the novel RXR partial agonist prevents
CSE-induced emphysematous changes
We assessed the efficacy of the novel RXR partial agonist
in CSE-induced emphysema (Fig. 1a). Intraperitoneal ad-
ministration of CSE to vehicle-treated mice significantly
increased Lm and DI values on day 28 compared to
PBS/vehicle mice. Treatment with 0.015% NEt-4IB sig-
nificantly suppressed the increases in Lm and DI values
compared to the increases in CSE/vehicle mice (Fig. 1b).
Representative light microscopic photographs of lung
sections are shown in Fig. 1c. Additionally, the Cst
values in CSE/vehicle mice on day 28 were significantly
increased compared to those of PBS/vehicle mice, and
treatment with NEt-4IB significantly attenuated the in-
crease in Cst compared to that observed in CSE/vehicle
mice (Fig. 1d).
Treatment with NEt-4IB suppresses established and
progressive emphysematous changes
Next, we assessed whether NEt-4IB could prevent the
progression of emphysematous changes (Fig. 2a). On the
seventh day after first intratracheal administration of
PPE, emphysematous changes in the lungs were already
observed in PPE-treated mice. Lm and DI were signifi-
cantly increased in PPE/vehicle mice compared with
Fig. 1 Treatment with a novel RXR partial agonist prevents CSE-induced emphysematous changes. a Experimental protocol. b (a) Lm values, (b)
DI values. c Representative photographs of H&E-stained lung tissue (magnification: X200) (a) PBS/vehicle, (b) CSE/vehicle, (c) CSE/NEt-4IB 0.015%.
(D) Cst values. The results for each group are expressed as the means ± SEM. This experiment was started with 7 mice in PBS/vehicle, and 11 mice
in CSE/vehicle, PPE/NEt-4IB 0.015%. No mice were died during the experimental period. * Significant differences (P < 0.05) between PBS/vehicle and
CSE/vehicle. # Significant differences (P < 0.05) between CSE/vehicle and CSE/NEt-4IB 0.005%. CSE, cigarette smoke extract
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PBS/vehicle mice on day 7 (Fig. 2b). To further evaluate
the progression of emphysematous changes, PPE/vehicle
mice were administered a second dose of PPE on day 7.
This additional PPE instillation significantly promoted
the increases in Lm and DI compared to those observed
in both PPE/vehicle mice on day 7 and PBS/vehicle mice
on day 21. Interestingly, treatment with NEt-4IB from
days 7 to 21 significantly suppressed the PPE-induced
increases in Lm and DI compared to those observed in
PPE/vehicle mice on day 21 (Fig. 2b). Representative
light microscopic photographs of lung sections are
shown in Fig. 2c. According to the pulmonary function
test, the Cst values in PPE/vehicle mice on day 7 did not
significantly increase compared to those of PBS/vehicle
mice. However, after the second PPE instillation, the Cst
values in PPE/vehicle mice on day 21 did significantly
increase compared to those of PBS/vehicle mice, and
treatment with NEt-4IB significantly suppressed this in-
crease in Cst value compared to the increase observed in
PPE/vehicle mice (Fig. 2d).
Treatment with NEt-4IB attenuates PPE-induced airway
inflammation
To determine whether treatment with NEt-4IB can
affect inflammatory changes in the lungs, we assessed
airway inflammation in BAL fluid or lung tissue in a
murine model of PPE-induced emphysema (Fig. 3a). The
numbers of macrophages, lymphocytes, and neutrophils
in BAL fluid were significantly increased in PPE/vehicle
mice compared to PBS/vehicle mice. Treatment with
NEt-4IB significantly reduced the numbers of total cells
and neutrophils in BAL fluid compared to those seen in
PPE/vehicle mice (Fig. 3b). The levels of KC and CXCL5
in BAL fluid and IFN-γ in lung tissue were also
Fig. 2 Treatment with NEt-4IB suppresses established and progressive emphysematous changes. a Experimental protocol. b (a) Lm values, (b) DI
values. c Representative photographs of H&E-stained lung tissue (magnification: X200) (a) PBS/vehicle on day 7, (b) PPE/vehicle on day 7, (c) PBS/
vehicle on day 21, (d) PPE/vehicle on day 21, (e) PPE/NEt-4IB 0.015% on day 21. d Cst values. The results for each group are expressed as the
means ± SEM. This experiment was started with 8 mice in each group, and no mice were died during the experimental period. * Significant
differences (P < 0.05) between PBS/vehicle and PPE/vehicle. # Significant differences (P < 0.05) between PPE/vehicle and PPE/NEt-4IB 0.015% †
Significant differences (P < 0.05) between PPE/vehicle on day 7 and PPE/vehicle on day 21
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significantly increased in PPE/vehicle mice compared to
PBS/vehicle mice (Fig. 3c a, b, f ). Treatment with
NEt-4IB significantly reduced the levels of KC and
CXCL5 in BAL fluid and IFN-γ and IL-17 in lung tissue
compared to levels in PPE/vehicle mice (Fig. 3c a, b, f,
g). PPE did not significantly increase the level of perforin
in the lung compared to that of PBS/vehicle mice; never-
theless, treatment with NEt-4IB tended to reduce this
augmentation (Fig. 3c e). IL-6 and IL-1β levels in the
BAL fluid were below the threshold of measurement
sensitivity (Fig. 3c c, d), and there was no significant dif-
ference in the levels of TNF-α in lung tissue (Fig. 3c h).
Fig. 3 Treatment with NEt-4IB attenuates PPE-induced airway inflammation. a Experimental protocol. b Cell composition in BAL fluid. c (a) KC, (b)
CXCL5 (c) IL-6, (d) IL-1β in BAL fluid, and (e) perforin, (f) IFN-γ, (g) IL-17, and (h) TNF-α in the lungs. The results for each group are expressed as the
means ± SEM. This experiment was started with 10 mice in each group, and no mice were died during the experimental period. * Significant
differences (P < 0.05) between PBS/vehicle and PPE/vehicle. # Significant differences (P < 0.05) between PPE/vehicle and PPE/NEt-4IB 0.015%
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Treatment with NEt-4IB improves the PPE-induced
proteinase/anti-proteinase imbalance in BAL fluid and
the reduction of anti-oxidant activity in the airway
A proteinase/anti-proteinase imbalance has been implicated
in COPD pathogenesis in both experimental models and
humans. We assessed the MMP-9/TIMP-1 balance on day
4 and anti-oxidant activity on day 1 (Fig. 4a). The MMP-9/
TIMP-1 ratio in the BAL fluid was significantly increased
in PPE/vehicle mice compared with PBS/vehicle mice, but
treatment with NEt-4IB significantly decreased the MMP-
9/TIMP-1 ratio (Fig. 4b). Oxidative stress has also been
associated with the pathogenesis of COPD in both experi-
mental models and humans. Therefore, we assessed
anti-oxidant activity in BAL fluid and serum on day 1.
Anti-oxidant activity in the BAL fluid was significantly re-
duced in PPE/vehicle mice compared to PBS/vehicle mice,
and treatment with NEt-4IB significantly improved the
reduction of anti-oxidant activity in BAL fluid. This
anti-oxidant activity in the serum was not reduced by PPE
instillation, although treatment with NEt-4IB significantly
increased the anti-oxidant activity compared to that in
PBS/vehicle and PPE/vehicle mice (Fig. 4c).
Fig. 4 Treatment with NEt-4IB improves the PPE-induced proteinase/anti-proteinase imbalance and impairment of anti-oxidant activity. a Experimental
protocol. b MMP-9/TIMP-2 ratio in BAL fluid on day 4. c Anti-oxidant activity measured by the BAP test in BAL fluid (a) and in serum (b) on day 1. The
results for each group are expressed as the means ± SEM. This experiment was started with 10 mice in each group, and no mice were
died during the experimental period. * Significant differences (P < 0.05) between PBS/vehicle and PPE/vehicle. # Significant differences (P < 0.05)
between PPE/vehicle and PPE/NEt-4IB 0.015%. BAP, bio-anti-oxidant power
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Treatment with NEt-4IB suppressed PPE-induced VEGF
expression in the airway
Angiogenesis-induced airway remodelling plays an im-
portant role in the pathogenesis and the development of
COPD [21]. We assessed the levels of VEGF in the acute
phase on day 2 and the late phase on day 14 in our
mouse model (Fig. 5a), and the levels of VEGF signifi-
cantly increased in PPE/vehicle mice compared to PBS/
vehicle mice. Treatment with NEt-4IB significantly at-
tenuated the increase of VEGF levels in PPE/NEt-4IB
mice compared to PPE/vehicle mice on both day 2 and
day 14 (Fig. 5b, c).
Comparison of the effects of RXR partial agonist (NEt-4IB)
and full agonist (bexarotene) on Lm, DI and Cst
We compared the efficacy of the novel RXR partial
agonist (NEt-4IB 0.015%) with that of the RXR full
agonist (bexarotene 0.015%) (Fig. 6a). Treatment of
PPE-treated mice with bexarotene (PPE/bexarotene
0.015%) significantly suppressed the increases in Lm and
DI values observed in PPE/vehicle mice (Fig. 6b). Repre-
sentative light microscopic photographs of lung sections
are shown in (Fig. 6c). According to the pulmonary
function test, treatment with bexarotene and NEt-4IB
significantly suppressed the PPE-induced increase in
static lung compliance observed in PPE/vehicle mice
(Fig. 6d). There were no significant differences in Lm,
DI, and Cst values between PPE/NEt-4IB 0.015% mice
and PPE/bexarotene 0.015% mice. These data suggest
that RXR agonists have the potential to attenuate the de-
velopment of emphysema.
Comparison of adverse events associated with NEt-4IB
and bexarotene regarding the liver weight to body
weight ratio and serum parameters
The amount of feed intake per day per mouse was not
significantly different in each group (Additional file 2).
To assess the adverse effects associated with RXR ago-
nists, we measured the body and liver weight (Additional
file 2) and the liver weight to body weight (L/BW) ratio
and serum parameters (Table 1, Additional file 1).
Treatment with NEt-4IB significantly improved the
PPE-induced suppression of the ratio of BW change in a
dose-dependent manner (Additional file 1D), but liver
weight in PPE/NEt-4IB 0.05% mice significantly in-
creased compared to PPE/vehicle mice. Furthermore,
liver weight of PPE/bexarotene 0.015% mice was signifi-
cantly higher than that of PPE/NEt-4IB 0.05% mice
(Additional file 2). The L/BW ratio in PPE/NEt-4IB
0.015% mice was slightly increased compared to that of
PPE/vehicle mice, but there was no significant difference
between PBS/vehicle and PPE/NEt-4IB 0.015% mice. In
contrast, the L/BW ratio in PPE/bexarotene 0.015% mice
was significantly higher than in PBS/vehicle, PPE/vehicle,
and PPE/NEt-4IB 0.015% mice (Table 1). Regarding
serum parameters, the level of TGs in PPE/vehicle mice
Fig. 5 Treatment with NEt-4IB supresses PPE-induced VEGF expression in the airway. a Experimental protocol. b VEGF in BAL fluid on day 2, (c)
VEGF in BAL fluid on day 14. The results for each group are expressed as the means ± SEM. This experiment was started with 8 mice in each group,
and no mice were died during the experimental period. * Significant differences (P < 0.05) between PBS/vehicle and PPE/vehicle. # Significant
differences (P < 0.05) between PPE/vehicle and PPE/NEt-4IB 0.015%
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was significantly lower than that of PBS/vehicle mice.
Treatment with NEt-4IB 0.015% significantly improved
the PPE-induced suppression of TG, and there was no
significant difference between PBS/vehicle and PPE/
NEt-4IB 0.015% mice. In mice treated with bexarotene
0.015%, the TG level was significantly increased com-
pared to those of PBS/vehicle and PPE/NEt-4IB 0.015%
mice. Treatment with NEt-4IB 0.015% did not affect the
levels of glucose, AST, ALT, ALP, LAP, or AMY in blood
serum, which were measured to evaluate liver and pan-
creas damage. In contrast, serum levels of ALP and
AMY in bexarotene-treated mice were significantly in-
creased compared to those of PPE/vehicle mice, and
serum levels of ALP in bexarotene-treated mice were
significantly increased compared to those of PBS/vehicle
and PPE/NEt-4IB 0.015% mice (Table 1).
Discussion
In the present study, we demonstrated for the first time
that RXRs may have important roles in the development
of emphysema, and our novel RXR partial agonist
NEt-4IB exhibited therapeutic potential for use in a
murine model of emphysema. Our data clearly showed
that treatment with NEt-4IB significantly suppressed
histologic emphysematous changes and the increase in
Cst values, as supported not only by the attenuation of
Fig. 6 Comparison of the effects of the RXR partial agonist NEt-4IB and the full agonist bexarotene on Lm, DI and Cst. a Experimental protocol. b
(a) Lm values, (b) DI values. c Representative photographs of H&E-stained lung tissue (magnification: X200) (a) PBS/vehicle, (b) PBS/NEt-4IB 0.015%,
(c) PBS/bexarotene 0.015%, (d) PPE/vehicle, (e) PPE/NEt-4IB 0.015%, (f) PPE/bexarotene 0.015%. d Cst values. The results for each group are expressed
as the means ± SEM. This experiment was started with 8 mice in PBS/vehicle, PBS/NEt-4IB 0.015%, PBS/bexarotene 0.015%, and 10 mice in PPE/vehicle,
PPE/NEt-4IB 0.015%, PPE/bexarotene 0.015%. No mice were died during the experimental period. * Significant differences (P < 0.05) between PBS/
vehicle and PPE/vehicle. # Significant differences (P < 0.05) between PPE/vehicle and PPE/NEt-4IB 0.015% or PPE/bexarotene 0.015%
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neutrophil accumulation and expression of neutrophilic
chemotactic factors but also by improvements in the
proteinase/anti-proteinase imbalance and in the reduced
anti-oxidant activity. Furthermore, treatment with
NEt-4IB significantly attenuated the increased VEGF
levels in emphysematous mice, which is an important
factor for the development of airway remodelling, and
suppressed both established and progressive emphyse-
matous changes. These data acquired for both PPE- and
CSE-induced emphysema models suggest that the novel
RXR partial agonist NEt-4IB has the potential to attenu-
ate the development of emphysema.
RXR, retinoic acid receptor (RAR), and the associated
ligands play critical roles in the generation of the lungs.
High concentrations of retinoid binding protein and ret-
inoic acid binding protein are observed during the peri-
natal period [22]: furthermore, RAR and RXR play
important roles in the generation of the lungs and in
septation of the alveoli [23]. Many studies in animals
and humans have been conducted using retinol and ret-
inoid derivatives, which activate RAR and RXR. Am80,
which is an RAR alpha agonist, had therapeutic effects
in a murine model of emphysema [24]. In contrast,
all-trans retinoic acid improved the diffusing capacity of
the lung carbon monoxide (DLCO) and CT density
score in patients with emphysema with some adverse ef-
fects, although no clinical benefit was reported [25].
Palovarotene, a selective RARγ agonist, failed to induce
clinical effects in patients with moderate to severe
COPD [26]. These data suggest that RAR agonists alone
may not have sufficient therapeutic potential to pre-
vent and improve emphysema. RXRs function not
only as homodimers but also as permissive heterodi-
mers with PPAR and LXR [5]. Therefore, RXR agonists
may exert potential effects on RXR/RXR, PPARγ/RXR
and LXR/RXR.
Bexarotene, which is an RXR full agonist, is known to
be effective against cutaneous T cell lymphoma in
humans [9] and has been reported to have therapeutic
potential in animal models of type-2 diabetes [10],
Alzheimer’s disease [11], and Parkinson’s disease [12].
However, bexarotene has various strong adverse events,
such as weight gain, hepatomegaly, hypertriglyceridemia,
pancreatitis, and hypothyroidism [13]. Therefore, we de-
veloped a novel RXR partial agonist, NEt-4IB, that re-
duced adverse events in these assays, in contrast to full
agonists, even after 28 consecutive days of administra-
tion [15]. Partial agonists are drugs that bind to and acti-
vate a receptor but exert only partial effects on the
receptor relative to a full agonist. We believe that an im-
portant key property of partial agonists is that they dis-
play both agonistic and antagonistic effects. Weak
partial agonists are compounds that are able to produce
only a small percentage of the total response produced
by an agonist and that act predominantly as antagonists.
Strong partial agonists may come close to mimicking the
maximum effects of a full agonist and may display only
weak antagonistic ability. Clinically, partial agonists can
be used to activate receptors to give a desired submaxi-
mal response and prevent overstimulation of receptors,
which could result in adverse events. NEt-4IB was found
to have a maximum RXR activation efficacy of 55% com-
pared with full agonists based on a luciferase reporter
gene assay [15]. To assess the clinical advantages of
NEt-4IB compared to bexarotene, we compared the ef-
fects of NEt-4IB and bexarotene in a murine model of
PPE-induced emphysema. Treatment with bexarotene
attenuated PPE-induced emphysematous changes to the
same extent as treatment with NEt-4IB, but bexarotene
induced less favourable side effect profile than NEt-4IB
in the assays studied. We found that administration of
bexarotene induced hepatomegaly, hypertriglyceridemia,
and ALP and AMY elevation, which were not observed
upon treatment with NEt-4IB. Although we did not
evaluate the dose-related effects of bexarotene, the hu-
man equivalent dose (HED) [27] of bexarotene in the
mice in our study (HED 1.5 mg/kg) corresponded to ap-
proximately 20% of the dose of bexarotene used to
Table 1 The L/BW ratio and serum parameters as adverse effects of RXR agonists
PBS/vehicle PPE/vehicle PPE/NEt-4IB
0.015%
PPE/Bexarotene
0.015%
L/BW ratio 0.050 ± 0.002 0.049 ± 0.001 0.053 ± 0.001# 0.073 ± 0.002*, #, ##
TG (mg/dl) 173 ± 12 140 ± 11* 177 ± 11# 255 ± 17*, #, ##
Glucose (mg/dl) 482 ± 23 479 ± 21 565 ± 35 492 ± 30
AST (IU/L) 125 ± 13 151 ± 12 153 ± 19 123 ± 12
ALT (IU/L) 56 ± 9 66 ± 7 54 ± 5 31 ± 4*, #, ##
ALP (IU/L) 275 ± 10 303 ± 9 296 ± 6 406 ± 11*, #, ##
LAP (IU/L) 54 ± 2 51 ± 1 53 ± 1 52 ± 1
AMY (IU/L) 5352 ± 509 4608 ± 276 5155 ± 445 6049 ± 204#
*Significant differences (P < 0.05) between PBS/vehicle and PPE/vehicle or PPE/Bexarotene 0.015%. #Significant differences (P < 0.05) between PPE/vehicle and PPE/
NEt-4IB 0.015% or PPE/bexarotene 0.015%. ##Significant differences (P < 0.05) between PPE/NEt-4IB 0.015% and PPE/bexarotene 0.015%
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clinically treat cutaneous T cell lymphoma (300mg/m2). It
was demonstrated that even a low dose of bexarotene in-
duced hypertriglyceridemia and could cause pancreatitis
[28]. These data suggest that NEt-4IB treatment has
promising therapeutic potential without inducing the se-
vere adverse events associated with bexarotene treatment.
Accumulation of inflammatory cells, including neutro-
phils, macrophages, and CD8+ T cells, a proteinase/anti-
proteinase imbalance, apoptosis, and oxidative stress
may play important roles in the pathogenesis of COPD
[29]. Neutrophils, which secrete MMP-9, cathepsin G,
and neutrophil elastase, are a predictor of the disease
severity of the emphysematous component of COPD
[29, 30]. Human MMP-9 induced emphysema in a mur-
ine model [31], and an MMP-9/TIMP-1 imbalance was
observed in COPD patients with exacerbations [32].
According to these data, controlling neutrophilic inflam-
mation may prevent the progression of emphysema.
Various nuclear receptor agonists were reported to con-
trol neutrophil accumulation and the expression of
MMP-9, and agonists of PPARγ and LXR exerted some
anti-neutrophilic inflammatory and protective effects in
the development of emphysema in a murine model [3].
Bexarotene reduced the levels of MMPs and increased
the levels of TIMPs in human alveolar adenocarcinoma
cells [33] and in a rat model of cerebral ischaemia [34].
Our data show that treatment with NEt-4IB significantly
reduced the levels of IL-17, KC and CXCL5 in BAL fluid
and the levels of IFN-γ in lung tissue, consequently re-
ducing neutrophil accumulation and improving the
MMP-9/TIMP-1 imbalance in the airways. In the
present study, the levels of IL-6, IL-1β and TNF-α did
not increase after PPE-instillation. The cause of this is
likely that 50 U/kg PPE may not be sufficient for indu-
cing these cytokines in our murine model of emphy-
sema. While eosinophilic inflammation in the airway of
COPD patients has recently attracted significant clinical
attention, we previously demonstrated that NEt-4IB sig-
nificantly suppressed airway hyperresponsiveness and
eosinophil accumulation in the airways [20] and attenu-
ated the levels of IL-5, IL-13, and NO in BAL fluid.
NEt-4IB also reduced the numbers of CD4+ and CD8+ T
cells, TNF-α levels, and nuclear factor-κB (NF-κB) ex-
pression in lung tissue in a murine model of allergic
asthma [20]. Taken together, these findings indicate that
the novel RXR partial agonist NEt-4IB regulates airway
inflammation and prevents the progression of various
phenotypes of emphysema.
Oxidative stress plays important roles in the pathogen-
esis of COPD [35]. Smoke from cigarettes, wood, and
plastic contains high concentrations of free radicals and
other oxidants [35, 36]. Oxidative stress is increased in
smokers and patients with acute exacerbations of COPD
[37], and the levels of oxidants in exhaled breath
condensate are increased in patients with COPD [38].
PPARγ regulates gene transcription, acting as a heterodi-
mer with RXR, and PPARγ/RXR promotes Nrf2, which
regulates the transcription of genes, including the anti-
oxidant response element [39]. In the present study,
treatment with NEt-4IB significantly increased anti-oxi-
dant activity in BAL fluid compared to PPE/vehicle mice.
There was no significant difference in the anti-oxidant
activity in the serum between PBS/vehicle and PPE/ve-
hicle. Although intratracheal administration of 50 U/kg
of PPE could not induce systemic inflammation which
could reduce anti-oxidant activity in the serum,
treatment with NEt-4IB significantly increased the anti-
oxidant activity compared to PPE/vehicle mice. These
data suggest that NEt-4IB may have the potential to in-
duce anti-oxidant activity by the anti-oxidant response
element activation via PPARγ/RXR.
Chronic airway inflammation results in airway and
vascular remodelling in COPD as it does in asthma [21].
The air flow limitation caused by airway remodelling is
one of the important factors leading to the pathogenesis
of COPD [40]. VEGF could have important roles in air-
way inflammation, tissue remodelling, and angiogenesis
in COPD [21]. VEGF levels were significantly higher in
the sputum of COPD patients compared to non-smokers
[41] . The expression of VEGF in the bronchiolar epithe-
lium, bronchiolar vascular smooth muscle cells, and
bronchiolar airway smooth muscle cells was significantly
increased in COPD patients compared to non-COPD
patients [42]. In addition, the increased VEGF levels
were inversely correlated with the values of FEV1 in
COPD patients [42]. Furthermore, the blockade of VEGF
significantly suppressed small airway remodelling in a
rat model of COPD [43]. These data suggest that sup-
pression of VEGF in the airway may be a therapeutic
strategy to prevent the progression of COPD. Although
few data have been reported regarding the relationship
between angiogenesis and MMPs in the pathogenesis of
COPD, the levels of MMP-9 and VEGF in sputum were
significantly higher in asthma patients compared to
non-asthma patients, and the levels of MMP-9 were sig-
nificantly correlated with the levels of VEGF. Moreover,
administration of VEGF receptor inhibitor reduced the
levels of MMP-9 [44]. The agonists of PPARγ, RAR and
RXR are suggested to act as inhibitory NRs in the con-
text of angiogenesis via reduction of VEGFC production
in brown adipose tissue [45]. Although active all-trans
RA (ATRA), which is a strong pan RAR agonist, stimu-
lates angiogenesis and induces production of VEGFA
and VEGFR2 mRNA in human lung microvascular
endothelial cells, endogenous RA signalling may regulate
alveolar maintenance and repair [46]. Our data show
that treatment with NEt-4IB, which is a selective RXR
partial agonist, did not activate RARs and significantly
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suppressed the PPE-induced augmented VEGF levels in
BAL fluid in both acute and late phase emphysema.
These data suggest that a selective stimulation of RXR
by NEt-4IB may have a therapeutic potential to attenuate
the progression of airway remodelling by persistently
suppressing VEGF levels. In addition, the therapeutic
capability of NEt-4IB to improve the proteinase/anti-
proteinase imbalance may result of suppressing VEGF
production via NR signals.
Although the mechanism of RXR partial agonists in
the progression of emphysema are not fully elucidated,
NEt-4IB may play a critical role in controlling the accu-
mulation and activation of neutrophils by suppressing
IL-17, KC and CXCL5 and by regulating the activation
of Th1 cells. There are some limitations of this study de-
sign. First, we did not measure lung volumes. Lm can be
used as a surrogate for airspace size and contains both
alveoli and alveolar ducts, however it was reported that
there was a significant correlation between Lm and DI,
and DI is a more sensitive parameter for parenchymal al-
ternation than Lm in human lung [19]. In our study, the
values of Lm, DI and Cst which we measured to evaluate
emphysematous change of the lung were consistently at-
tenuated by the treatment with NEt-4IB. Although we
did not measure lung volumes, our data could evaluate
the effects of NEt-4IB in a murine model of emphysema.
Second, we could not apply the long-term CS-exposed
emphysema model, because this systematic protocol was
not approved by the institutional animal care and use
committee of Okayama University Medical School.
Conclusions
Our study demonstrated for the first time that treatment
with the novel RXR partial agonist NEt-4IB holds thera-
peutic potential for the development of emphysema. The
mechanism of this novel RXR partial agonist may be that
it plays a crucial role in attenuating neutrophilic airway
inflammation, correcting the proteinase/anti-proteinase
imbalance, and improving insufficient anti-oxidant activ-
ities. Although additional studies will be required to
demonstrate that NEt-4IB may partially and permissively
affect heterodimeric partners such as LXR or PPARs,
NEt-4IB could be a promising strategy for the treatment
of emphysema.
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vehicle, PPE/NEt-4IB 0.005%, PPE/NEt-4IB 0.015%, PPE/NEt-4IB 0.05%. No mice
were died during the experimental period. * Significant differences (P < 0.05)
between PBS/vehicle and PPE/vehicle. ** Significant differences (P< 0.05)
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vehicle, PPE/NEt-4IB 0.005%, PPE/NEt-4IB 0.015%, PPE/NEt-4IB 0.05%. No
mice were died during the experimental period. * Significant differences
(P< 0.05) between PPE/NEt-4IB 0.05% and PBS/vehicle, PBS/NEt-4IB 0.015%,
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(P< 0.05) between PPE/Bexarotene 0.015% and other groups. (PDF 29 kb)
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